Bevacimab IV Infusion

Introduction

Betamethasone dipropionate and salicylic acid are combined in topical formulations for the treatment of various skin conditions. Betamethasone dipropionate is a potent corticosteroid that reduces inflammation, redness, and itching, while salicylic acid acts as a keratolytic agent that helps to exfoliate the skin and enhance the absorption of the corticosteroid. This combination is effective in treating conditions like psoriasis, eczema, and dermatitis.

Uses

The combination of betamethasone dipropionate and salicylic acid is used for:

Managing inflammatory skin conditions such as psoriasis and eczema.
Reducing symptoms of dermatitis, including itching, redness, and scaling.
Improving the penetration and efficacy of topical corticosteroids by removing scales and crusts.

Brand Name	Bevacimab
Type	IV Infusion
Weight	400 mg/16 ml
Generic	Bevacizumab
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Betamethasone dipropionate, a potent corticosteroid, works by suppressing the inflammatory response through inhibition of leukocyte migration and reduction of inflammatory mediators. Salicylic acid enhances the absorption of betamethasone by breaking down the keratinized layer of the skin, which helps in the effective delivery of the corticosteroid to the target tissues.

How Long Does It Take to Work?

The effects of the combination treatment usually begin within a few days of application, with noticeable improvement in symptoms such as inflammation and itching typically observed within 1 to 2 weeks. The full therapeutic effect may take several weeks of continuous use.

Absorption

Betamethasone dipropionate is absorbed through the skin, with systemic absorption being minimal when applied topically. Salicylic acid enhances the penetration of betamethasone by softening and peeling the outer layer of the skin, increasing the efficacy of the corticosteroid.

Route of Elimination

Betamethasone dipropionate is metabolized primarily in the liver and excreted via the kidneys. Salicylic acid is metabolized to salicyluric acid and other metabolites, which are excreted in the urine.

Dosage

Patients should continue treatment until disease progression or unacceptable toxicity.

Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.

Administer 5 mg/kg when used in combination with bolus-IFL.
Administer 10 mg/kg when used in combination with FOLFOX4.
Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.

Non-Squamous Non-Small Cell Lung Cancer: (NSNSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.

Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.

Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).

Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: The recommended dose is 15 mg/kg every 3 weeks when administered in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until disease progression. Alternatively, 15 mg/kg every 3 weeks when administrated in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until disease progression.

The typical dosage for the combination product is to apply a thin layer to the affected area once or twice daily, depending on the severity of the condition and the recommendation of a healthcare provider. The dosage may vary based on the specific formulation and patient response.

Administration

Apply betamethasone dipropionate and salicylic acid topically as directed:

Clean and dry the affected area before application.
Apply a thin layer of the medication to the affected area and gently rub it in.
Wash hands after applying the medication.
Avoid contact with eyes and mucous membranes.

Side Effects

Common side effects include:

Skin irritation or burning sensation at the application site.
Dryness or peeling of the skin.
Redness or rash.

Less common but serious side effects may include systemic absorption effects, such as adrenal suppression or secondary infections.

Toxicity

Topical toxicity is rare but may occur if large areas are treated or if the medication is used for prolonged periods. Symptoms of toxicity include excessive skin thinning, striae (stretch marks), or systemic corticosteroid effects such as adrenal insufficiency.

Precautions

Use with caution in individuals with:

Skin infections, as corticosteroids can exacerbate infections.
History of hypersensitivity to corticosteroids or salicylic acid.
Diabetes, as corticosteroids may affect glucose metabolism.

Interaction

Interactions are minimal when used topically. However, combining with other topical treatments may increase the risk of skin irritation or adverse effects. Avoid using with other potent corticosteroids or topical agents without consulting a healthcare provider.

Disease Interaction

Use cautiously in patients with:

Systemic fungal infections, as corticosteroids may worsen these conditions.
Pre-existing skin conditions that may be aggravated by corticosteroids.
Renal or hepatic impairment, as systemic absorption, though minimal, may be altered.

Drug Interaction

There are no significant systemic drug interactions with topical use. However, combining with other topical treatments should be done cautiously to avoid increased risk of adverse effects.

Food Interactions

There are no known significant food interactions with betamethasone dipropionate and salicylic acid when used topically.

Pregnancy Use

The use of betamethasone dipropionate and salicylic acid during pregnancy should be limited to short-term use and only if the benefits outweigh the risks. Consult a healthcare provider before using during pregnancy.

Lactation Use

Caution is advised when using this combination during breastfeeding. Minimal amounts of the drug may be absorbed systemically, and while topical use is unlikely to pose significant risks, it is recommended to apply the medication away from the breast area and consult a healthcare provider.

Acute Overdose

Acute overdose from topical application is unlikely. In cases of excessive application, symptoms may include severe skin irritation or systemic effects such as adrenal suppression. Seek medical attention if overdose is suspected.

Contraindication

The combination is contraindicated in patients with:

Known hypersensitivity to betamethasone, salicylic acid, or other components of the formulation.
Active viral, fungal, or bacterial infections of the skin.
Rosacea or perioral dermatitis, where corticosteroids may worsen the condition.

Use Direction

Apply the medication exactly as prescribed by a healthcare provider. Avoid using more than directed, and do not use on broken or infected skin. Follow all usage instructions and consult your provider if you experience any adverse effects or if symptoms persist.

Storage Conditions

Store the medication at room temperature, away from moisture and heat. Keep the container tightly closed and out of reach of children. Do not use beyond the expiration date.

Volume of Distribution

The volume of distribution for betamethasone dipropionate is relatively low when used topically, as systemic absorption is minimal. Salicylic acid also has low systemic distribution due to its local application.

Half Life

The half-life of betamethasone dipropionate in the systemic circulation is approximately 3 to 5 hours. However, its effects on the skin may last longer due to its local action. The half-life of salicylic acid in systemic circulation is about 2 to 3 hours.

Clearance

Betamethasone dipropionate is metabolized primarily by the liver and excreted in the urine. Salicylic acid is also metabolized by the liver to form conjugated metabolites that are excreted in the urine. Clearance rates may vary based on individual patient factors.

See in details version Bevacimab IV Infusion 400 mg/16 ml also Bevacimab IV Infusion 400 mg/16 ml in bangla